55 related articles for article (PubMed ID: 2614173)
21. Adoptive immunotherapy of human cancer using low-dose recombinant interleukin 2 and lymphokine-activated killer cells.
Schoof DD; Gramolini BA; Davidson DL; Massaro AF; Wilson RE; Eberlein TJ
Cancer Res; 1988 Sep; 48(17):5007-10. PubMed ID: 3261630
[TBL] [Abstract][Full Text] [Related]
22. Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer.
Stewart JA; Belinson JL; Moore AL; Dorighi JA; Grant BW; Haugh LD; Roberts JD; Albertini RJ; Branda RF
Cancer Res; 1990 Oct; 50(19):6302-10. PubMed ID: 2205379
[TBL] [Abstract][Full Text] [Related]
23. A new strategy using autologous dendritic cells and lymphokine-activated killer cells for cancer immunotherapy: efficient maturation of DCs by co-culture with LAK cells in vitro.
Yano Y; Ueda Y; Itoh T; Fuji N; Okugawa K; Naito K; Imura K; Kohara J; Hayashi T; Nakane K; Matsuura Y; Kawai K; Yamagishi H
Oncol Rep; 2006 Jul; 16(1):147-52. PubMed ID: 16786138
[TBL] [Abstract][Full Text] [Related]
24. T cells and monocytes regulate the generation and functional activity of natural killer-derived lymphokine-activated killer cells.
Atzpodien J; Gulati SC
Stem Cells; 1993 Nov; 11(6):511-8. PubMed ID: 8111310
[TBL] [Abstract][Full Text] [Related]
25. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
[TBL] [Abstract][Full Text] [Related]
26. Increased non-major histocompatibility complex-restricted lytic activity in melanoma patients vaccinated with cytokine gene-transfected autologous tumor cells.
Möller P; Möller H; Sun Y; Dorbic T; Henz BM; Wittig B; Schadendorf D
Cancer Gene Ther; 2000 Jul; 7(7):976-84. PubMed ID: 10917199
[TBL] [Abstract][Full Text] [Related]
27. [The anti-tumor efficacy of lymphokine-activated killer (LAK) cells induced in vitro from peripheral blood lymphocytes of patients with malignant glioma].
Shimizu K; Miyao Y; Okamoto Y; Matsui Y; Ushio Y; Tsuda N; Hayakawa T; Ishida N; Mogami H
No To Shinkei; 1986 Mar; 38(3):265-71. PubMed ID: 3085695
[TBL] [Abstract][Full Text] [Related]
28. Sequential TNF and TGF-beta regulation of expansion and induction of cytotoxicity in long-term cultures of lymphokine-activated killer cells.
Koberda J; Przepiorka D; Moser RP; Grimm EE
Lymphokine Cytokine Res; 1994 Apr; 13(2):139-45. PubMed ID: 8061115
[TBL] [Abstract][Full Text] [Related]
29. Generation of human lymphokine-activated killer cells following brief exposure to high dose interleukin 2.
Horton SA; Oldham RK; Yannelli JR
Cancer Res; 1990 Mar; 50(6):1686-92. PubMed ID: 2306722
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of lymphokine-activated killer cells generation in vitro by soluble factors released from mixed human tumor and peripheral blood mononuclear adherent cells culture.
Eisenthal A; Barbarsteyn E; Gitstein G; Lifschitz-Mercer B
Cancer Invest; 2006 Feb; 24(1):28-34. PubMed ID: 16466989
[TBL] [Abstract][Full Text] [Related]
31. Long-term growth of lymphokine-activated killer (LAK) cells: role of anti-CD3, beta-IL 1, interferon-gamma and -beta.
Ochoa AC; Gromo G; Alter BJ; Sondel PM; Bach FH
J Immunol; 1987 Apr; 138(8):2728-33. PubMed ID: 2435804
[TBL] [Abstract][Full Text] [Related]
32. Augmentation of lymphokine-activated killer cell activity by lentinan.
Tani M; Tanimura H; Yamaue H; Tsunoda T; Iwahashi M; Noguchi K; Tamai M; Hotta T; Mizobata S
Anticancer Res; 1993; 13(5C):1773-6. PubMed ID: 8267381
[TBL] [Abstract][Full Text] [Related]
33. [Clinical efficacy of LAK cell adoptive immunotherapy in advanced cancer patients].
Toge T; Takayama T; Kegoya Y; Kuninobu H; Yamaguchi Y; Hattori T
Nihon Geka Gakkai Zasshi; 1989 Sep; 90(9):1455-8. PubMed ID: 2586438
[TBL] [Abstract][Full Text] [Related]
34. Interleukin 2 and lymphokine-activated killer cell therapy: analysis of a bolus interleukin 2 and a continuous infusion interleukin 2 regimen.
Clark JW; Smith JW; Steis RG; Urba WJ; Crum E; Miller R; McKnight J; Beman J; Stevenson HC; Creekmore S
Cancer Res; 1990 Nov; 50(22):7343-50. PubMed ID: 2224862
[TBL] [Abstract][Full Text] [Related]
35. Retaliation against tumor cells showing aberrant HLA expression using lymphokine activated killer-derived T cells.
Falk CS; Noessner E; Weiss EH; Schendel DJ
Cancer Res; 2002 Jan; 62(2):480-7. PubMed ID: 11809699
[TBL] [Abstract][Full Text] [Related]
36. Interleukin 15 induction of lymphokine-activated killer cell function against autologous tumor cells in melanoma patient lymphocytes by a CD18-dependent, perforin-related mechanism.
Gamero AM; Ussery D; Reintgen DS; Puleo CA; Djeu JY
Cancer Res; 1995 Nov; 55(21):4988-94. PubMed ID: 7585540
[TBL] [Abstract][Full Text] [Related]
37. Exogenous interleukin 2 recruits in vitro lymphokine-activated killer activity by in vivo activated lymphocytes.
Lamers HJ; Gratama JW; van Putten WL; Stoter G; Bolhuis RL
Cancer Res; 1991 May; 51(9):2324-8. PubMed ID: 2015597
[TBL] [Abstract][Full Text] [Related]
38. [Clinical application of adoptive immunotherapy by cytotoxic T lymphocytes induced from tumor-infiltrating lymphocytes].
Yamaue H; Tanimura H; Tsunoda T; Iwahashi M; Tani M; Inoue M; Tamai M
Nihon Gan Chiryo Gakkai Shi; 1990 May; 25(5):978-89. PubMed ID: 2391445
[TBL] [Abstract][Full Text] [Related]
39. Lymphokine-activated killing of autologous and allogeneic short-term cultured head and neck squamous carcinomas.
Leess FR; Bredenkamp JK; Lichtenstein A; Mickel RA
Laryngoscope; 1989 Dec; 99(12):1255-61. PubMed ID: 2601539
[TBL] [Abstract][Full Text] [Related]
40. A new high-yield continuous cell-culture system for lymphokine-activated killer cells.
Noto T; Tokuda Y; Nakamura Y; Suzuki A; Watanabe K; Yamamura M; Tajima T; Mitomi T; Nishijima K
Cancer Immunol Immunother; 1989; 30(1):1-4. PubMed ID: 2598170
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]